Bosutinib Isomer 1, Free Base (CAS 1391063-17-4)
ACCÈS RAPIDE AUX LIENS
Bosutinib Isomer 1, Free Base, represents a variant of the bosutinib molecule with an altered structural arrangement, diverging from the parent compound in its specific interaction with cellular targets. Despite its deviation from the canonical bosutinib structure, leading to a diminished capacity to inhibit a broad spectrum of kinases, this isomer retains a potent activity against Bcr-Abl kinase, a pivotal enzyme in certain cellular signaling pathways. Its ability to selectively engage and inhibit Bcr-Abl kinase positions Bosutinib Isomer 1, Free Base as useful in the exploration of the complex signaling mechanisms mediated by this kinase. In research contexts, it facilitates the dissection of Bcr-Abl's role within various cellular processes, offering insights into the enzyme's contribution to the regulation of cell growth and proliferation pathways.
Bosutinib Isomer 1, Free Base (CAS 1391063-17-4) Références
- Évaluation in vitro des effets inhibiteurs dépendants du temps sur l'activité du CYP2C8 et du CYP3A par quatorze inhibiteurs de protéines kinases. | Filppula, AM., et al. 2014. Drug Metab Dispos. 42: 1202-9. PMID: 24713129
Informations pour la commande
| Nom du produit | Ref. Catalogue | COND. | Prix HT | QTÉ | Favoris | |
Bosutinib Isomer 1, Free Base, 25 mg | sc-396752 | 25 mg | $75.00 |